Allan Marchington is the Head of Life Sciences at Intermediate Capital Group PLC (ICG), a FTSE 100 asset manager with over $82Bn under management. The ICG life sciences team was recently announced as one of two recipients of the UK Government LIFTs initiative. Their strategy is focussed on investing in life science companies developing medicines to treat diseases for which there are no, or limited treatment options available for patients. Allan has been a Life Science investor for the last 20 years. Prior to joining ICG, Allan was formerly a Founding Partner at Bridge Valley Ventures, prior to this was at Apposite Capital, and Abingworth. Allan has also had several operational roles during his career and was Senior Vice President at Millennium Pharmaceuticals in Cambridge, Mass. Allan joined Millennium following their acquisition of the company he founded, Cambridge Discovery Chemistry, where he was CEO. Allan began his career working for seven years in R&D at Pfizer. Allan serves on the BVCA Pensions and Private Capital Expert Panel.
